Shares in UK-based Vaccitech climbed by more than 40% after it reported encouraging early results from its ChAdOx1 vaccine platform used in a hepatitis B therapy, which looked strongest when combined with Bristol Myers Squibb’s immuno-oncology product Opdivo.
Vaccitech’s Immunotherapy Combo With Opdivo Shows Hepatitis B Promise
Searching For A Functional Cure
The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.

More from Business
Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
More from Scrip
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.